TY  - JOUR
PY  - 2024//
TI  - Treatment for opioid use disorder: population estimates - United States, 2022
JO  - MMWR: Morbidity and mortality weekly report
A1  - Dowell, Deborah
A1  - Brown, Samantha
A1  - Gyawali, Shiromani
A1  - Hoenig, Jennifer
A1  - Ko, Jean
A1  - Mikosz, Christina
A1  - Ussery, Emily
A1  - Baldwin, Grant
A1  - Jones, Christopher M.
A1  - Olsen, Yngvild
A1  - Tomoyasu, Naomi
A1  - Han, Beth
A1  - Compton, Wilson M.
A1  - Volkow, Nora D.
SP  - 567
EP  - 574
VL  - 73
IS  - 25
N2  - In 2022, 81,806 opioid-involved overdose deaths were reported in the United States, more than in any previous year. Medications for opioid use disorder (OUD), particularly buprenorphine and methadone, substantially reduce overdose-related and overall mortality. However, only a small proportion of persons with OUD receive these medications. Data from the 2022 National Survey on Drug Use and Health were applied to a cascade of care framework to estimate and characterize U.S. adult populations who need OUD treatment, receive any OUD treatment, and receive medications for OUD. In 2022, 3.7% of U.S. adults aged ≥18 years needed OUD treatment. Among these, only 25.1% received medications for OUD. Most adults who needed OUD treatment either did not perceive that they needed it (42.7%) or received OUD treatment without medications for OUD (30.0%). Compared with non-Hispanic Black or African American and Hispanic or Latino adults, higher percentages of non-Hispanic White adults received any OUD treatment. Higher percentages of men and adults aged 35-49 years received medications for OUD than did women and younger or older adults. Expanded communication about the effectiveness of medications for OUD is needed. Increased efforts to engage persons with OUD in treatment that includes medications are essential. Clinicians and other treatment providers should offer or arrange evidence-based treatment, including medications, for patients with OUD. Pharmacists and payors can work to make these medications available without delays.<p />  <p>Language: en</p>
LA  - en
SN  - 0149-2195
UR  - http://dx.doi.org/10.15585/mmwr.mm7325a1
ID  - ref1
ER  -